Oral lichen planus: update on etiopathogenesis, diagnosis and treatment

References

• Setterfield, J.F., Neill, S., Shirlaw, P.J., Theron, J., Vaughan, R., Escudier, M., Challacombe, S.J., Black, M.M. The vulvovaginal gingival syndrome: a severe subgroup of lichen planus with characteristic clinical features and a novel association with the class II HLA DQB1*0201 allele. J. Am. Acad. Dermatol. 2006, 55, 98–113.
   PubMedGoogle Scholar
• Quispel, R., van Boxel, O.S., Schipper, M.E., Sigurdsson, V., Canninga-van Dijk, M.R., Kerckhoffs, A., Smout, A.J., Samsom, M., Schwartz, M.P. High prevalence of esophageal involvement in lichen planus: a study using magnification chromoendoscopy. Endoscopy 2009, 41, 187–193.
   PubMedGoogle Scholar
• Thorne, J.E., Jabs, D.A., Nikolskaia, O.V., Mimouni, D., Anhalt, G.J., Nousari, H.C. Lichen planus and cicatrizing conjunctivitis: characterization of five cases. Am. J. Ophthalmol. 2003, 136, 239–243.
   PubMed Web of Science ®Google Scholar
• Mignogna, M.D., Lo Russo, L., Fedele, S. Gingival involvement of oral lichen planus in a series of 700 patients. J. Clin. Periodontol. 2005, 32, 1029–1033.
   PubMedGoogle Scholar
• González Moles, M.A., Esteban, F., Ruiz-Avila, I., Gil Montoya, J.A., Brener, S., Bascones-Martínez, A., Muñoz, M. A role for the substance P/NK-1 receptor complex in cell proliferation and apoptosis in oral lichen planus. Oral Dis. 2009, 15, 162–169.
   PubMedGoogle Scholar
• Pinholt, E.M., Rindum, J., Pindborg, J.J. Oral cancer: a retrospective study of 100 Danish cases. Br. J. Oral Maxillofac. Surg. 1997, 35, 77–80.
   PubMedGoogle Scholar
• Ingafou, M., Leao, J.C., Porter, S.R., Scully, C. Oral lichen planus: a retrospective study of 690 British patients. Oral Dis. 2006, 12, 463–468.
   PubMedGoogle Scholar
• Bricker, S.L. Oral lichen planus: a review. Semin. Dermatol. 1994, 13, 87–90.
   PubMedGoogle Scholar
• Thorn, J.J., Holmstrup, P., Rindum, J., Pindborg, J.J. Course of various clinical forms of oral lichen planus. A prospective follow-up study of 611 patients. J. Oral Pathol. 1988, 17, 213–218.
   PubMedGoogle Scholar
• Ismail, S.B., Kumar, S.K., Zain, R.B. Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation. J. Oral Sci. 2007, 49, 89–106.
   PubMedGoogle Scholar
• Al-Hashimi, I., Schifter, M., Lockhart, P.B., Wray, D., Brennan, M., Migliorati, C.A., Axéll, T., Bruce, A.J., Carpenter, W., Eisenberg, E., Epstein, J.B., Holmstrup, P., Jontell, M., Lozada-Nur, F., Nair, R., Silverman, B., Thongprasom, K., Thornhill, M., Warnakulasuriya, S., van der Waal, I. Oral lichen planus and oral lichenoid lesions: diagnostic and therapeutic considerations. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2007, 103 Suppl, S25.e1–S25.12.
   Google Scholar
• Thornhill, M.H., Pemberton, M.N., Simmons, R.K., Theaker, E.D. Amalgam-contact hypersensitivity lesions and oral lichen planus. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2003, 95, 291–299.
   PubMedGoogle Scholar
• Carrozzo, M., Thorpe, R. Oral lichen planus: a review. Minerva Stomatol. 2009, 58, 519–537.
   PubMedGoogle Scholar
• Walsh, L.J., Savage, N.W., Ishii, T., Seymour, G.J. Immunopathogenesis of oral lichen planus. J. Oral Pathol. Med. 1990, 19, 389–396.
   PubMed Web of Science ®Google Scholar
• Carrozzo, M., Uboldi de Capei, M., Dametto, E., Fasano, M.E., Arduino, P., Broccoletti, R., Vezza, D., Rendine, S., Curtoni, E.S., Gandolfo, S. Tumor necrosis factor-alpha and interferon-gamma polymorphisms contribute to susceptibility to oral lichen planus. J. Invest. Dermatol. 2004, 122, 87–94.
   PubMed Web of Science ®Google Scholar
• Fujita, H., Kobayashi, T., Tai, H., Nagata, M., Hoshina, H., Nishizawa, R., Takagi, R., Yoshie, H. Assessment of 14 functional gene polymorphisms in Japanese patients with oral lichen planus: a pilot case-control study. Int. J. Oral Maxillofac. Surg. 2009, 38, 978–983.
   PubMedGoogle Scholar
• Bouma, G., Xia, B., Crusius, J.B., Bioque, G., Koutroubakis, I., Von Blomberg, B.M., Meuwissen, S.G., Peña, A.S. Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). Clin. Exp. Immunol. 1996, 103, 391–396.
   PubMedGoogle Scholar
• Simark-Mattsson, C., Bergenholtz, G., Jontell, M., Eklund, C., Seymour, G.J., Sugerman, P.B., Savage, N.W., Dahlgren, U.I. Distribution of interleukin-2, -4, -10, tumour necrosis factor-alpha and transforming growth factor-beta mRNAs in oral lichen planus. Arch. Oral Biol. 1999, 44, 499–507.
   PubMed Web of Science ®Google Scholar
• Carrozzo, M. Oral diseases associated with hepatitis C virus infection. Part 2: lichen planus and other diseases. Oral Dis. 2008, 14, 217–228.
   PubMedGoogle Scholar
• Carrozzo, M., Brancatello, F., Dametto, E., Arduino, P., Pentenero, M., Rendine, S., Porter, S.R., Lodi, G., Scully, C., Gandolfo, S. Hepatitis C virus-associated oral lichen planus: is the geographical heterogeneity related to HLA-DR6? J. Oral Pathol. Med. 2005, 34, 204–208.
   PubMedGoogle Scholar
• Wenzel, J., Scheler, M., Proelss, J., Bieber, T., Tüting, T. Type I interferon-associated cytotoxic inflammation in lichen planus. J. Cutan. Pathol. 2006, 33, 672–678.
   PubMed Web of Science ®Google Scholar
• Rice, P.J., Hamburger, J. Oral lichenoid drug eruptions: their recognition and management. Dent. Update 2002, 29, 442–447.
   Google Scholar
• van der Meij, E.H., van der Waal, I. Lack of clinicopathologic correlation in the diagnosis of oral lichen planus based on the presently available diagnostic criteria and suggestions for modifications. J. Oral Pathol. Med. 2003, 32, 507–512.
   PubMed Web of Science ®Google Scholar
• van der Waal, I. Oral lichen planus and oral lichenoid lesions; a critical appraisal with emphasis on the diagnostic aspects. Med Oral Patol Oral Cir Bucal, 2009, 14, 310–314.
   PubMedGoogle Scholar
• Eisenberg, E. Clinicopathologic patterns of oral lichenoid lesions. Oral Maxillofac Surg Clin North Am, 1994, 6, 445.
   Google Scholar
• Mutasim, D.F., Adams, B.B. Immunofluorescence in dermatology. J. Am. Acad. Dermatol. 2001, 45, 803–22; quiz 822.
   PubMed Web of Science ®Google Scholar
• Helander, S.D., Rogers, R.S. 3rd. The sensitivity and specificity of direct immunofluorescence testing in disorders of mucous membranes. J. Am. Acad. Dermatol. 1994, 30, 65–75.
   PubMed Web of Science ®Google Scholar
• Kanokvalai, K, Sukhum, J., Supenya, V., Pinkaew S., Sutthipinittharm P. Direct immunofluorescence study in patients with lichen planus. Int J Dermatol, 2007, 46, 1237–1241.
   PubMedGoogle Scholar
• Camisa, C., Neff, J.C., Olsen, R.G. Use of indirect immunofluorescence in the lupus erythematosus/lichen planus overlap syndrome: an additional diagnostic clue. J. Am. Acad. Dermatol. 1984, 11, 1050–1059.
   PubMedGoogle Scholar
• Inaloz, H.S., Chowdhury, M.M.U., Motley, R.J. Scarring alopecia in LE/LP overlap syndrome: a case report. J Eur Acad Dermatol Venereol, 2000, 15, 171–174.
   Google Scholar
• Rhodus, N.L., Cheng, B., Ondrey, F. Th1/Th2 cytokine ratio in tissue transudates from patients with oral lichen planus. Mediators Inflamm. 2007, 2007, 19854.
   PubMed Web of Science ®Google Scholar
• Krutchkoff, D.J., Cutler, L., Laskowski, S. Oral lichen planus: the evidence regarding potential malignant transformation. J. Oral Pathol. 1978, 7, 1–7.
   PubMedGoogle Scholar
• van der Meij, E.H., Schepman, K.P., van der Waal, I. The possible premalignant character of oral lichen planus and oral lichenoid lesions: a prospective study. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2003, 96, 164–171.
   PubMedGoogle Scholar
• Gandolfo, S., Richiardi, L., Carrozzo, M., Broccoletti, R., Carbone, M., Pagano, M., Vestita, C., Rosso, S., Merletti, F. Risk of oral squamous cell carcinoma in 402 patients with oral lichen planus: a follow-up study in an Italian population. Oral Oncol. 2004, 40, 77–83.
   PubMed Web of Science ®Google Scholar
• Lanfranchi-Tizeira, H.E., Aguas, S.C., Sano, S.M. Malignant transformation of atypical oral lichen planus: a review of 32 cases. Med. Oral 2003, 8, 2–9.
   PubMedGoogle Scholar
• Mignogna, M.D., Lo Muzio, L., Lo Russo, L., Fedele, S., Ruoppo, E., Bucci, E. Clinical guidelines in early detection of oral squamous cell carcinoma arising in oral lichen planus: a 5-year experience. Oral Oncol. 2001, 37, 262–267.
   PubMed Web of Science ®Google Scholar
• Lozada-Nur, F. Oral lichen planus and oral cancer: is there enough epidemiologic evidence? Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2000, 89, 265–266.
   PubMedGoogle Scholar
• Fatahzadeh, M., Rinaggio, J., Chiodo, T. Squamous cell carcinoma arising in an oral lichenoid lesion. J. Am. Dent. Assoc. 2004, 135, 754–9; quiz 796.
   PubMedGoogle Scholar
• Lo Muzio, L., Mignogna, M.D., Favia, G., Procaccini, M., Testa, N.F., Bucci, E. The possible association between oral lichen planus and oral squamous cell carcinoma: a clinical evaluation on 14 cases and a review of the literature. Oral Oncol. 1998, 34, 239–246.
   PubMedGoogle Scholar
• Mignogna, M.D., Lo Russo, L., Fedele, S., Ruoppo, E., Califano, L., Lo Muzio, L. Clinical behaviour of malignant transforming oral lichen planus. Eur. J. Surg. Oncol. 2002, 28, 838–843.
   PubMedGoogle Scholar
• Markopoulos, A.K., Antoniades, D., Papanayotou, P., Trigonidis, G. Malignant potential of oral lichen planus; a follow-up study of 326 patients. Oral Oncol. 1997, 33, 263–269.
   PubMedGoogle Scholar
• Mignogna, M.D., Fedele, S., Lo Russo, L., Mignogna, C., de Rosa, G., Porter, S.R. Field cancerization in oral lichen planus. Eur. J. Surg. Oncol. 2007, 33, 383–389.
   PubMedGoogle Scholar
• van der Meij, E.H., Mast, H., van der Waal, I. The possible premalignant character of oral lichen planus and oral lichenoid lesions: a prospective five-year follow-up study of 192 patients. Oral Oncol. 2007, 43, 742–748.
   PubMed Web of Science ®Google Scholar
• Mattsson, U., Jontell, M., Holmstrup, P. Oral lichen planus and malignant transformation: is a recall of patients justified? Crit. Rev. Oral Biol. Med. 2002, 13, 390–396.
   PubMedGoogle Scholar
• Scully, C., Beyli, M., Ferreiro, M.C., Ficarra, G., Gill, Y., Griffiths, M., Holmstrup, P., Mutlu, S., Porter, S., Wray, D. Update on oral lichen planus: etiopathogenesis and management. Crit. Rev. Oral Biol. Med. 1998, 9, 86–122.
   PubMedGoogle Scholar
• Scully, C., Eisen, D., Carrozzo, M. Management of oral lichen planus. Am. J. Clin. Dermatol. 2000, 1, 287–306.
   PubMedGoogle Scholar
• Thomson, M.A., Hamburger, J., Stewart, D.G., Lewis, H.M. Treatment of erosive oral lichen planus with topical tacrolimus. J. Dermatolog. Treat. 2004, 15, 308–314.
   PubMedGoogle Scholar
• Byrd, J.A., Davis, M.D., Bruce, A.J., Drage, L.A., Rogers, R.S. 3rd. Response of oral lichen planus to topical tacrolimus in 37 patients. Arch. Dermatol. 2004, 140, 1508–1512.
   PubMed Web of Science ®Google Scholar
• Branchet, M.C., Boisnic, S., Pascal, F., Ben Slama, L., Rostin, M., Szpirglas, H. [Topical tretinoin in the treatment of lichen planus and leukoplakia of the oral mucosa. A biochemical evaluation of the keratinization]. Ann. Dermatol. Venereol. 1994, 121, 464–469.
   PubMedGoogle Scholar
• Eisen, D. Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: An open trial. J. Am. Acad. Dermatol. 1993, 28, 609–612.
   PubMed Web of Science ®Google Scholar
• Setterfield, J.F., Black, M.M., Challacombe, S.J. The management of oral lichen planus. Clin. Exp. Dermatol. 2000, 25, 176–182.
   PubMedGoogle Scholar
• Plemons, J.M., Rees, T.D., Zachariah, N.Y. Absorption of a topical steroid and evaluation of adrenal suppression in patients with erosive lichen planus. Oral Surg. Oral Med. Oral Pathol. 1990, 69, 688–693.
   PubMedGoogle Scholar
• Vincent, S.D., Fotos, P.G., Baker, K.A., Williams, T.P. Oral lichen planus: the clinical, historical, and therapeutic features of 100 cases. Oral Surg. Oral Med. Oral Pathol. 1990, 70, 165–171.
   PubMedGoogle Scholar
• Lozada-Nur, F., Huang, M.Z., Zhou, G.A. Open preliminary clinical trial of clobetasol propionate ointment in adhesive paste for treatment of chronic oral vesiculoerosive diseases. Oral Surg. Oral Med. Oral Pathol. 1991, 71, 283–287.
   PubMedGoogle Scholar
• Mollaoglu, N. Oral lichen planus: a review. Br. J. Oral Maxillofac. Surg. 2000, 38, 370–377.
   PubMedGoogle Scholar
• Silverman, S. Jr, Gorsky, M., Lozada-Nur, F., Giannotti, K. A prospective study of findings and management in 214 patients with oral lichen planus. Oral Surg. Oral Med. Oral Pathol. 1991, 72, 665–670.
   PubMedGoogle Scholar
• Eisen, D. The therapy of oral lichen planus. Crit. Rev. Oral Biol. Med. 1993, 4, 141–158.
   PubMedGoogle Scholar
• Boisnic, S., Licu, D., Ben Slama, L., Branchet-Gumila, M.C., Szpirglas, H., Dupuy, P. Topical retinaldehyde treatment in oral lichen planus and leukoplakia. Int. J. Tissue React. 2002, 24, 123–130.
   PubMedGoogle Scholar
• Buajeeb, W., Kraivaphan, P., Pobrurksa, C. Efficacy of topical retinoic acid compared with topical fluocinolone acetonide in the treatment of oral lichen planus. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 1997, 83, 21–25.
   PubMed Web of Science ®Google Scholar
• Eisen, D., Ellis, C.N., Duell, E.A., Griffiths, C.E., Voorhees, J.J. Effect of topical cyclosporine rinse on oral lichen planus. A double-blind analysis. N. Engl. J. Med. 1990, 323, 290–294.
   PubMed Web of Science ®Google Scholar
• Bécherel, P.A., Chosidow, O., Boisnic, S., Moyal-Barraco, M., Pelisse, M., Reigneau, O., Francès, C. Topical cyclosporine in the treatment of oral and vulvar erosive lichen planus: a blood level monitoring study. Arch. Dermatol. 1995, 131, 495–496.
   PubMed Web of Science ®Google Scholar
• Sieg, P., Von Domarus, H., Von Zitzewitz, V., Iven, H., Färber, L. Topical cyclosporin in oral lichen planus: a controlled, randomized, prospective trial. Br. J. Dermatol. 1995, 132, 790–794.
   PubMed Web of Science ®Google Scholar
• Ruzicka, T., Assmann, T., Homey, B. Tacrolimus: the drug for the turn of the millennium? Arch. Dermatol. 1999, 135, 574–580.
   PubMedGoogle Scholar
• Böhm, M., Beissert, S., Schwarz, T., Metze, D., Luger, T. Bullous pemphigoid treated with mycophenolate mofetil. Lancet 1997, 349, 541.
   PubMed Web of Science ®Google Scholar
• Grundmann-Kollmann, M., Podda, M., Ochsendorf, F., Boehncke, W.H., Kaufmann, R., Zollner, T.M. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch. Dermatol. 2001, 137, 870–873.
   PubMed Web of Science ®Google Scholar
• Basara, N., Blau, W.I., Kiehl, M.G., Römer, E., Rudolphi, M., Bischoff, M., Kirsten, D., Sanchez, H., Günzelmann, S., Fauser, A.A. Efficacy and safety of mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant recipient. Transplant. Proc. 1998, 30, 4087–4089.
   PubMedGoogle Scholar
• Nousari, H.C., Goyal, S., Anhalt, G.J. Successful treatment of resistant hypertrophic and bullous lichen planus with mycophenolate mofetil. Arch. Dermatol. 1999, 135, 1420–1421.
   PubMedGoogle Scholar
• Frieling, U., Bonsmann, G., Schwarz, T., Luger, T.A., Beissert, S. Treatment of severe lichen planus with mycophenolate mofetil. J. Am. Acad. Dermatol. 2003, 49, 1063–1066.
   PubMed Web of Science ®Google Scholar
• Nylander Lundqvist, E., Wahlin, Y.B., Hofer, P.A. Methotrexate supplemented with steroid ointments for the treatment of severe erosive lichen ruber. Acta Derm. Venereol. 2002, 82, 63–64.
   PubMedGoogle Scholar
• Rozycki, T.W., Rogers, R.S. 3rd, Pittelkow, M.R., McEvoy, M.T., el-Azhary, R.A., Bruce, A.J., Fiore, J.P., Davis, M.D. Topical tacrolimus in the treatment of symptomatic oral lichen planus: a series of 13 patients. J. Am. Acad. Dermatol. 2002, 46, 27–34.
   PubMed Web of Science ®Google Scholar
• Ruzicka, T., Bieber, T., Schöpf, E., Rubins, A., Dobozy, A., Bos, J.D., Jablonska, S., Ahmed, I., Thestrup-Pedersen, K., Daniel, F., Finzi, A., Reitamo, S. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N. Engl. J. Med. 1997, 337, 816–821.
   PubMed Web of Science ®Google Scholar
• Fung, J.J., Todo, S., Tzakis, A., Demetris, A., Jain, A., Abu-Elmaged, K., Alessiani, M., Starzl, T.E. Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant. Proc. 1991, 23, 14–21.
   PubMedGoogle Scholar
• Kelly, P.A., Burckart, G.J., Venkataramanan, R. Tacrolimus: a new immunosuppressive agent. Am. J. Health. Syst. Pharm. 1995, 52, 1521–1535.
   PubMed Web of Science ®Google Scholar
• Meingassner, J.G., Stütz, A. Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases? J. Invest. Dermatol. 1992, 98, 851–855.
   PubMed Web of Science ®Google Scholar
• Aoyama, H., Tabata, N., Tanaka, M., Uesugi, Y., Tagami, H. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. Br. J. Dermatol. 1995, 133, 494–496.
   PubMed Web of Science ®Google Scholar
• Vente, C., Reich, K., Rupprecht, R., Neumann, C. Erosive mucosal lichen planus: response to topical treatment with tacrolimus. Br. J. Dermatol. 1999, 140, 338–342.
   PubMed Web of Science ®Google Scholar
• Reich, K., Vente, C., Neumann, C. Topical tacrolimus for pyoderma gangrenosum. Br. J. Dermatol. 1998, 139, 755–757.
   PubMedGoogle Scholar
• Kaliakatsou, F., Hodgson, T.A., Lewsey, J.D., Hegarty, A.M., Murphy, A.G., Porter, S.R. Management of recalcitrant ulcerative oral lichen planus with topical tacrolimus. J. Am. Acad. Dermatol. 2002, 46, 35–41.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration: FDA Public Health Advisory: Elidel (pimecrolimus) cream and Protopic (tacrolimus) ointment. 3-10-2005.
   Google Scholar
• Becker, J.C., Houben, R., Vetter, C.S., Bröcker, E.B. The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report. BMC Cancer 2006, 6, 7.
   PubMed Web of Science ®Google Scholar
• Swift, J.C., Rees, T.D., Plemons, J.M., Hallmon, W.W., Wright, J.C. The effectiveness of 1% pimecrolimus cream in the treatment of oral erosive lichen planus. J. Periodontol. 2005, 76, 627–635.
   PubMed Web of Science ®Google Scholar
• Passeron, T., Lacour, J.P., Fontas, E., Ortonne, J.P. Treatment of oral erosive lichen planus with 1% pimecrolimus cream: a double-blind, randomized, prospective trial with measurement of pimecrolimus levels in the blood. Arch. Dermatol. 2007, 143, 472–476.
   PubMed Web of Science ®Google Scholar
• Volz, T., Caroli, U., Lüdtke, H., Bräutigam, M., Kohler-Späth, H., Röcken, M., Biedermann, T. Pimecrolimus cream 1% in erosive oral lichen planus–a prospective randomized double-blind vehicle-controlled study. Br. J. Dermatol. 2008, 159, 936–941.
   PubMed Web of Science ®Google Scholar
• Soria, A., Agbo-Godeau, S., Taïeb, A., Francès, C. Treatment of refractory oral erosive lichen planus with topical rapamycin: 7 cases. Dermatology (Basel). 2009, 218, 22–25.
   PubMedGoogle Scholar
• Cheng, A., Mann, C. Oral erosive lichen planus treated with efalizumab. Arch. Dermatol. 2006, 142, 680–682.
   PubMedGoogle Scholar
• Gottlieb, A.B., Gordon, K.B., Hamilton, T.K. Maintenance of efficacy and safety with continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: final phase IIIb study results. Poster presented at the 63rd Annual Meeting of the American Academy of Dermatology; February 18-22, 2005, New Orleans, La.
   Google Scholar
• Connolly, M., Armstrong, J.S., Buckley, D.A. Infliximab treatment for severe orogenital ulceration in Behçet’s disease. Br. J. Dermatol. 2005, 153, 1073–1075.
   PubMedGoogle Scholar
• Spencer-Green G. Etanercept (Enbrel): update on therapeutic use. Ann Rheum Dis, 2000, 59 Suppl 1, 146–149.
   PubMedGoogle Scholar
• Yarom, N. Etanercept for the management of oral lichen planus. Am. J. Clin. Dermatol. 2007, 8, 121.
   PubMedGoogle Scholar
• Fivenson, D.P., Mathes, B. Treatment of generalized lichen planus with alefacept. Arch. Dermatol. 2006, 142, 151–152.
   PubMed Web of Science ®Google Scholar
• Chamian, F., Lin, S.L., Lee, E., Kikuchi, T., Gilleaudeau, P., Sullivan-Whalen, M., Cardinale, I., Khatcherian, A., Novitskaya, I., Wittkowski, K.M., Krueger, J.G., Lowes, M.A. Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis. J Transl Med, 2007, 7, 5–27.
   Google Scholar
• Grillo-López, A.J. Rituximab: an insider’s historical perspective. Semin. Oncol. 2000, 27, 9–16.
   PubMed Web of Science ®Google Scholar
• Cooper, H.L., Healy, E., Theaker, J.M., Friedmann, P.S. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab). Clin. Exp. Dermatol. 2003, 28, 366–368.
   PubMed Web of Science ®Google Scholar
• Barnadas, M., Roe, E., Brunet, S., Garcia, P., Bergua, P., Pimentel, L., Puig, L., Francia, A., García, R., Gelpí, C., Sierra, J., Coll, P., Alomar, A. Therapy of paraneoplastic pemphigus with Rituximab: a case report and review of literature. J. Eur. Acad. Dermatol. Venereol. 2006, 20, 69–74.
   PubMedGoogle Scholar
• Cutler, C., Miklos, D., Kim, H.T., Treister, N., Woo, S.B., Bienfang, D., Klickstein, L.B., Levin, J., Miller, K., Reynolds, C., Macdonell, R., Pasek, M., Lee, S.J., Ho, V., Soiffer, R., Antin, J.H., Ritz, J., Alyea, E. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006, 108, 756–762.
   PubMed Web of Science ®Google Scholar
• Salopek, T.G., Logsetty, S., Tredget, E.E. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J. Am. Acad. Dermatol. 2002, 47, 785–788.
   PubMed Web of Science ®Google Scholar